这是一篇来自已证抗体库的有关人类 EGLN1的综述,是根据11篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合EGLN1 抗体。
EGLN1 同义词: C1orf12; ECYT3; HALAH; HIF-PH2; HIFPH2; HPH-2; HPH2; PHD2; SM20; ZMYND6; egl nine homolog 1; HIF-prolyl hydroxylase 2; egl nine-like protein 1; hypoxia-inducible factor prolyl hydroxylase 2; prolyl hydroxylase domain-containing protein 2; zinc finger MYND domain-containing protein 6

Novus Biologicals
兔 多克隆
  • 免疫印迹基因敲除验证; 人类; 1:5000; 图 2D
Novus Biologicals EGLN1抗体(Novus Biologicals, NB100-137)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:5000 (图 2D). elife (2017) ncbi
兔 多克隆
  • 免疫印迹; 人类; 图 1c
Novus Biologicals EGLN1抗体(Novus Biologicals, NB100-137)被用于被用于免疫印迹在人类样本上 (图 1c). Mol Cancer (2015) ncbi
兔 多克隆
  • 免疫沉淀; 人类
  • 免疫印迹; 人类; 图 8
  • 免疫沉淀; 灵长类动物
  • 免疫印迹; 灵长类动物
Novus Biologicals EGLN1抗体(Novus Biologicals, NB100-137)被用于被用于免疫沉淀在人类样本上, 被用于免疫印迹在人类样本上 (图 8), 被用于免疫沉淀在灵长类动物样本上 和 被用于免疫印迹在灵长类动物样本上. PLoS ONE (2015) ncbi
兔 多克隆
  • 免疫印迹; 人类
  • 免疫印迹; 小鼠; 图 5,6
Novus Biologicals EGLN1抗体(Novus, NB100-137)被用于被用于免疫印迹在人类样本上 和 被用于免疫印迹在小鼠样本上 (图 5,6). Nat Commun (2015) ncbi
兔 多克隆
  • 免疫组化基因敲除验证; 小鼠; 1:100; 图 4a
Novus Biologicals EGLN1抗体(Novus Biologicals, 100-2219)被用于被用于免疫组化基因敲除验证在小鼠样本上浓度为1:100 (图 4a). PLoS ONE (2014) ncbi
圣克鲁斯生物技术
小鼠 单克隆(H-8)
  • proximity ligation assay; 人类; 1:20; 图 2a
圣克鲁斯生物技术 EGLN1抗体(Santa Cruz, sc-271835)被用于被用于proximity ligation assay在人类样本上浓度为1:20 (图 2a). Oncotarget (2017) ncbi
赛信通(上海)生物试剂有限公司
兔 多克隆
  • 免疫印迹; 人类; 1:1000; 图 5e
赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling, 3293)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5e). Nat Commun (2016) ncbi
兔 多克隆
  • 免疫印迹; 小鼠; 图 1
赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling Technology, 3293)被用于被用于免疫印迹在小鼠样本上 (图 1). Skelet Muscle (2016) ncbi
兔 多克隆
  • 免疫印迹; 人类; 1:1000; 图 4c
赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling, 3293)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4c). Nat Cell Biol (2016) ncbi
兔 单克隆(D31E11)
  • 免疫印迹; 小鼠; 图 3a
赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling, 4835)被用于被用于免疫印迹在小鼠样本上 (图 3a). Genes Dev (2014) ncbi
兔 单克隆(D31E11)
  • 免疫印迹; 小鼠; 1:1000
赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling Technology, 4835)被用于被用于免疫印迹在小鼠样本上浓度为1:1000. J Bone Miner Res (2014) ncbi
文章列表
  1. Miles A, Burr S, Grice G, Nathan J. The vacuolar-ATPase complex and assembly factors, TMEM199 and CCDC115, control HIF1? prolyl hydroxylation by regulating cellular iron levels. elife. 2017;6: pubmed 出版商
  2. Kozlova N, Wottawa M, Katschinski D, Kristiansen G, Kietzmann T. Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. Oncotarget. 2017;8:9885-9898 pubmed 出版商
  3. Oh E, Kim J, Kim J, Kim S, Lee J, Hong S, et al. NQO1 inhibits proteasome-mediated degradation of HIF-1α. Nat Commun. 2016;7:13593 pubmed 出版商
  4. Shin J, Nunomiya A, Kitajima Y, Dan T, Miyata T, Nagatomi R. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway. Skelet Muscle. 2016;6:5 pubmed 出版商
  5. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, et al. The LINK-A lncRNA activates normoxic HIF1? signalling in triple-negative breast cancer. Nat Cell Biol. 2016;18:213-24 pubmed 出版商
  6. Högel H, Miikkulainen P, Bino L, Jaakkola P. Hypoxia inducible prolyl hydroxylase PHD3 maintains carcinoma cell growth by decreasing the stability of p27. Mol Cancer. 2015;14:143 pubmed 出版商
  7. Kumar P, Gullberg U, Olsson I, Ajore R. Myeloid translocation gene-16 co-repressor promotes degradation of hypoxia-inducible factor 1. PLoS ONE. 2015;10:e0123725 pubmed 出版商
  8. Hsiao H, Hsu T, Liu W, Hsieh W, Chou T, Wu Y, et al. Deltex1 antagonizes HIF-1α and sustains the stability of regulatory T cells in vivo. Nat Commun. 2015;6:6353 pubmed 出版商
  9. Zheng X, Zhai B, Koivunen P, Shin S, Lu G, Liu J, et al. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev. 2014;28:1429-44 pubmed 出版商
  10. Cheng S, Xing W, Pourteymoor S, Mohan S. Conditional disruption of the prolyl hydroxylase domain-containing protein 2 (Phd2) gene defines its key role in skeletal development. J Bone Miner Res. 2014;29:2276-86 pubmed 出版商
  11. Zimmermann A, Morrison S, Hu M, Li S, Nauta A, Sorkin M, et al. Epidermal or dermal specific knockout of PHD-2 enhances wound healing and minimizes ischemic injury. PLoS ONE. 2014;9:e93373 pubmed 出版商